AdNull

AdNull is a replication-deficient adenovirus type 5 (Ad5) vector that lacks a translatable expression cassette or transgene. Developed by Weill Medical College of Cornell University, it serves as a negative control or placebo in preclinical and clinical research. Its primary use is to provide a baseline for comparing the safety and efficacy of therapeutic gene vectors, specifically AdVEGF-All6A+ (also known as XC001), which expresses vascular endothelial growth factor (VEGF) isoforms. By administering AdNull, researchers can distinguish the host response to the viral vector itself from the effects produced by the therapeutic gene. It has been employed in the EXACT trial involving patients with diffuse coronary artery disease and refractory angina.

Other names

AdNull-Weill Medical College of Cornell University-coronary artery disease